The synthesis of data from mouse models and human-derived materials supports a speculative model where the crosstalk between BC cells and the microenvironment defines the metastasis pattern in carriers of GPVs in BCSGs.
Abstract
More than three decades have passed since the identification of BRCA1 as the first breast cancer susceptibility gene (BCSG). Since then, substantial progress has been made in pinpointing BCSGs and estimating the associated risk of developing BC. Simultaneously, new challenges and open questions have also emerged, such as the potential associations between BCSGs and metastasis in BC patients. In this review, we discuss available data from clinical and experimental studies assessing the association between germline pathogenic variants (GPVs) in BCSGs and metastasis pattern. To help guide future studies addressing the current knowledge gaps, the review outlines clinical outcomes and four variables to be considered: 1) age and ethnicity; 2) clinical, molecular, and pathological characteristics; 3) treatment response; and 4) the specificity of BSCG variants. The synthesis of data from mouse models and human-derived materials supports a speculative model where the crosstalk between BC cells and the microenvironment defines the metastasis pattern in carriers of GPVs in BCSGs. An experimental framework is proposed for testing this model in future studies that could parallel comprehensive clinical studies addressing the outlined clinical outcomes and variables.
Beyond the attractive potential to surrogate the tumor tissue testing, to overcome the cancer spatial and temporal heterogeneity, and to monitor the tumor mutational profile over time, accurately detecting all clinically relevant BRCA genetic variants and epigenetic modifications using LB remains technically challengin...
L. Incorvaia, V. Gristina, F. Pepe et al.· ESMO Open· 0 citations
Focusing on acquired resistance as a core bottleneck in precision therapy, mechanisms underlying anti-Human Epidermal Growth Factor Receptor 2 (HER2) resistance and primary/secondary resistance to immune checkpoint inhibitors (ICIs) were systematically dissected, while also addressing immune-related adverse events and...
ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical locatio...
Nisha Manav, Akanksha Kashyap, Lakshay Malhotra et al.· Cancer Reports· 0 citations
The challenges and opportunities for early cancer detection and interception in the context of pediatric cancer predisposition are exemplified by the paradigm cancer predisposition disorder, Li-Fraumeni syndrome. More than 85% of patients with Li-Fraumeni Syndrome harbour germline TP53 mutations. The genetic and phen...
SLC7A11 is identified as a non-canonical regulator of ECM/integrin-mediated FAK survival signaling in brain metastatic breast cancer cells, indicating that FAK signaling contributes to BCBM tumor maintenance and that it's inhibition can effectively suppress tumor growth.
Kevin Michael Hughley, Mauricio J. Reginato· 0 citations
Intratumor heterogeneity (ITH), the coexistence of diverse subclones within a single tumor, may pose a major challenge to effective chemotherapy in breast cancer. This cellular diversity contributes to treatment failure, residual disease, and early relapse by enabling tumor adaptation and therapeutic resistance. Althou...
Aria Dianati, Andre Dekker, A. Wesselius et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.